Schisanhenol ameliorates oxLDL ‐caused endothelial dysfunction by inhibiting LOX ‐1 signaling
Environmental Toxicology · 2023
DOI: 10.1002/tox.23788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2023. Verfasst von Tsan-Hung Chiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Scavenger Receptors, Class E, Atherosclerosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Asia University.
Abstract (Originalsprache)
Atherosclerotic lesions play a critical role in leading cardiovascular diseases. Oxidized low‐density lipoprotein (OxLDL) is a vital risk factor for atherosclerosis since it acts a crucial role in endothelial dysfunction and foam cell formation. Schisanhenol , a composition extracted from the fruit of Schisandra rubriflora , has been reported to have antioxidative effects on human LDL oxidation. This study investigates whether Schisanhenol protects against oxLDL‐mediated endothelial damage by modulating the lectin‐like oxLDL receptor‐1 (LOX‐1)‐mediated inflammatory processes. Human umbilical vein endothelial cells (HUVECs) were pre‐treated with 10 or 20 μM Schisanhenol for 2 h and then exposed to 150 μg/mL oxLDL. We revealed that Schisanhenol reduced oxLDL‐enhanced LOX‐1 expression. We also found that oxLDL down‐regulated endothelial nitric oxide synthase (eNOS) as well as activated inducible NOS (iNOS), thereby enhancing the generation of nitric oxide (NO). Moreover, oxLDL elevated the expression levels of phosphorylated‐p38MAPK, subsequently promoting NF‐κB‐modulated inflammatory responses. Pretreatment with Schisanhenol exerted significant cytoprotective function in all the above‐mentioned detrimental events. Results from this present study reveal that Schisanhenol has a potential therapeutic effect on preventing oxLDL‐induced endothelial injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.
- Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
- Integration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
- School of Post-Baccalaureate Chinese Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan.
- Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Rehabilitation, Asia University Hospital, Taichung, Taiwan.
ORCID-Profile: Kun-Ling Tsai, Hsiu-Chung Ou
Förderung
- Asia University
Zitieren
APA
Chiu, T. H., Ku, C. W., Ho, T. J., Tsai, K. L., Yang, Y. D., Ou, H. C., & Chen, H. I. (2023). Schisanhenol ameliorates oxLDL ‐caused endothelial dysfunction by inhibiting LOX ‐1 signaling. Environmental Toxicology. https://doi.org/10.1002/tox.23788
Vancouver
Chiu TH, Ku CW, Ho TJ, Tsai KL, Yang YD, Ou HC, et al. Schisanhenol ameliorates oxLDL ‐caused endothelial dysfunction by inhibiting LOX ‐1 signaling. Environmental Toxicology. 2023. doi:10.1002/tox.23788
BibTeX
@article{Chiu2023,
author = {Chiu, Tsan-Hung and Ku, Chang-Wen and Ho, Tsung-Jung and Tsai, Kun-Ling and Yang, Yi-Dung and Ou, Hsiu-Chung and Chen, Hsiu-I},
title = {Schisanhenol ameliorates oxLDL ‐caused endothelial dysfunction by inhibiting LOX ‐1 signaling},
journal = {Environmental Toxicology},
year = {2023},
doi = {10.1002/tox.23788}
}
EUVIMED